A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.

[1]  S. Kubo,et al.  Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma , 2023, Radiology case reports.

[2]  Kelly Oechsel,et al.  Spontaneous rupture of nontraumatic hepatic artery pseudoaneurysm , 2023, Journal of Surgical Case Reports.

[3]  J. Shindoh,et al.  The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis , 2022, Oncology.

[4]  S. Mochida,et al.  Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib , 2022, Internal medicine.

[5]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[6]  A. Pariente,et al.  Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms. , 2021, JAMA oncology.

[7]  M. Kurosaki,et al.  The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan , 2020, Journal of Gastroenterology.

[8]  A. Yamamoto,et al.  Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas , 2020, Oncology.

[9]  V. Kashyap,et al.  The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. , 2020, Journal of vascular surgery.

[10]  T. Koshiishi,et al.  Intratumoral pseudoaneurysm within a liver metastasis of gastric cancer: a case report , 2020, Surgical case reports.

[11]  Masanari Sekine,et al.  Rupture of Hepatic Pseudoaneurysm Formed Nine Years after Carbon Ion Radiotherapy for Hepatocellular Carcinoma , 2019, Internal medicine.

[12]  Hiroki Sato,et al.  Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma , 2019, World journal of gastroenterology.

[13]  Y. Funahashi,et al.  Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma , 2019, Cancer investigation.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  S. Hori,et al.  Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres , 2015, Japanese Journal of Radiology.

[16]  Z. Sajjad,et al.  Intratumoral pseudoaneurysms in hepatocellular carcinoma: do they occur de novo without any prior intervention? A tertiary care center experience of 6 years , 2015, Acta radiologica.

[17]  Y. Imai,et al.  Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[18]  Yi-tao Ding,et al.  Life-threatening hemorrhage after liver radiofrequency ablation successfully controlled by transarterial embolization. , 2012, World journal of hepatology.

[19]  R. Poon,et al.  Vascular Changes in Hepatocellular Carcinoma , 2008, Anatomical record.

[20]  R. Baron,et al.  Extrahepatic metastases of hepatocellular carcinoma. , 2000, Radiology.

[21]  H. Weskott,et al.  [B-flow--a new method for detecting blood flow]. , 2000, Ultraschall in der Medizin.

[22]  S. Olliff,et al.  Hepatic artery aneurysm. , 1999, The British journal of radiology.

[23]  M. Fujita,et al.  Color Doppler flow imaging of liver tumors. , 1990, AJR. American journal of roentgenology.